Jason Stienecker, DO
Pulmonary Disease · Lima, OHNPI 1538455720
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $302,208 of the $397,081 with a category attached, or 76.1%. United Therapeutics Corporation accounts for 86.8% of it on its own, with 30 other manufacturers making up the rest. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 696 payments — averaging $570.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$345K
- Olympus America Inc.$15K
- Merck$12K
- Actelion Pharmaceuticals US, Inc.$9K
- Intuitive Surgical$6K
- AstraZeneca$5K
- plus $6K from 25 others
Across 5 payments — averaging $1867.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$9K
What the payments were for
- Consulting fees$20,9805%
- Speaking & faculty fees$302,20876%
- Travel & lodging$54,86814%
- Food & beverage$15,9114%
- Education$3,1141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 446 | $344,699 |
| Olympus America Inc. | 31 | $14,760 |
| Merck | 19 | $12,289 |
| Actelion Pharmaceuticals US, Inc. | 30 | $8,570 |
| Intuitive Surgical | 24 | $6,229 |
| AstraZeneca | 19 | $4,866 |
| Bayer | 11 | $3,086 |
| Galvanize Therapeutics, Inc | 2 | $615 |
| Regeneron Healthcare Solutions, Inc. | 8 | $462 |
| Boehringer Ingelheim | 22 | $339 |
| GSK | 32 | $294 |
| Healthmyne, Inc. | 1 | $133 |
| Genentech USA, Inc. | 7 | $109 |
| Sunovion Pharmaceuticals Inc. | 8 | $85 |
| Sanofi | 5 | $75 |
| Mylan Specialty L.p. | 5 | $71 |
| Johnson & Johnson(2 entities) | 4 | $47 |
| Grifols USA, LLC | 3 | $47 |
| Philips North America LLC | 3 | $44 |
| Medtronic | 1 | $44 |
| Electromed, Inc. | 3 | $43 |
| Insmed, Inc. | 2 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Vapotherm Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Amgen | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Apria Healthcare LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$149,311
- ORENITRAM$70,037
- Spiration Valve System$11,898
- WINREVAIR$11,696
- REMODULIN$10,284
- OPSUMIT$8,180
- ION$3,000
- Adempas$2,944
- Da Vinci Surgical System$2,742
- SVS$1,800
- SPiN Vision Video Processor$1,200
- ALIYA SYSTEM$600
- DUPIXENT$236
- HealthMyne$133
How this compares
$397,081 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 36 | $900,564 |
| OpsumitMacitentan | 63 | $797,129 |
| AdempasRiociguat | 50 | $641,626 |
| OfevNintedanib Esylate | 26 | $345,138 |
| Orenitram ErTreprostinil Diolamine | 13 | $305,255 |
| UptraviSelexipag | 12 | $260,691 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $123,540 |
| NucalaMepolizumab | 22 | $94,056 |
| Ambrisentan | 12 | $91,959 |
| Spiriva RespimatTiotropium Bromide | 70 | $72,107 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $35,746 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $25,057 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $22,446 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $14,244 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $13,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $8,570 | $1,057,82075 claims |
| BayerAdempas | $3,086 | $641,62650 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $339 | $442,302114 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $294 | $278,484187 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,866 | $35,65854 claims |
| MerckDulera | $12,289 | $10,04015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Lima
- Marc RovnerLima$71K
- Sarat KuchipudiLima$23K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.